Critical reviews in oncology/hematology · 2020
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lai Eleonora, Astara Giorgio, Ziranu Pina, Pretta Andrea, Migliari Marco, Dubois Marco, Donisi Clelia, Mariani Stefano, Liscia Nicole, Impera Valentino, Persano Mara, Tolu Simona, Balconi Francesca, Pinna Giovanna, Spanu Dario, Pireddu Annagrazia, Saba Giorgio, Camera Silvia, Musio Francesca, Puzzoni Marco, Pusceddu Valeria, Madeddu Clelia, Casadei Gardini Andrea, Scartozzi Mario
Аннотация
Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy has been explored in this disease in order to improve survival outcomes. Nowadays, scientific research is focusing especially on immune checkpoint inhibitors, in particular anti-PD1, anti-PD-L1 and anti-CTLA4 monoclonal antibodies (mAbs), as single-agent or in combination with other immunotherapy agents, target therapies, anti-vascular endothelial growth factor (VEGF) and other agents targeting specific molecular pathways. Other immunotherapy strategies have been assessed or are under investigation in advanced HCC, namely cytokines, adoptive cell therapy, oncolytic virus, cancer vaccines. Each treatment presents specific efficacy and toxicity profiles, strictly related to their mechanism of action and to advanced HCC tumour microenvironment (TME). The aim of this review is to outline the state-of-the-art of immunotherapy in advanced HCC treatment, highlighting data on already investigated treatment strategies, safety and toxicity (including HBV/HCV-related HCC), and ongoing clinical trials focusing on new promising therapeutic weapons.